Payment & Shipping Terms:
|CAS:||77472-70-9||Appearanve:||White Fine Powder|
|Application:||Nootropics||Biological Half-life:||3–5 Hours|
|Formula:||C12H14N2O2||Molar Mass:||218.3 G/mol|
Peak Nootropics Phenylpiracetam Carphedon Anti Amnesic CAS 77472-70-9
Phenylpiracetam also called is a phenylatedanalog of the drug piracetam which was developed in 1983 in Russia where it is available as a prescription drug. Research on animals has indicated that phenylpiracetam may have anti-amnesic, antidepressant , anticonvulsant, antipsychotic, anxiolytic and memory enhanvement effects.
|Store at||Room temperature|
Given the apparent stimulant like nature of this nootropic, it’s probably best taken sporadically on an “as needed” basis, rather than being a staple. Common sense dictates that tolerance with prolonged use could become an issue, and while there’s been no research conducted on this it’s probably best to cycle phenylpiracetam.
Absorption data for humans remains unpublished. The phenotropil product insert states phenylpiracetam is absorbed fast and exhibits a 100% oral bioavailability. The manufacturer states peak blood concentrations are achieved at 1 hour and the half life for phenylpiracetam is 3-5 hours.
|Items of Analysis||Requirements||Results|
|Appearance||Off-white to white powder||Conforms|
|Loss on drying||≤1.0%||0.6%|
|Residue on ingnition||≤0.3%||0.05%|
|Conclusion||The product conforms to in House Standard|
The Russian producers of Phenotropil claim phenylpiracetam is able to fight fatigue, depression, is helpful in the treatment of epilepsy, and treatment of conditions resulting from low brain oxygen. Unfortunately lots of the research backing these claims up is either unavailable online or is written in Russian. What little research is available either in full text or abstract is discussed below.
One study involving 61 patients with different forms of epilepsy compared phenotropil and AEDs (anti epilepsy drugs) vs AED’s alone. The authors concluded that the addition of phenotropil reduced seizure frequency and induced positive EEG changes. One study involving 400 patients who had recently suffered ischemic stroke showed phenylpiracetam improved recovery rate significantly when compared to placebo.
The main focus of the available and translated research revolves around people with a cognitive deficit following stroke, brain injury or encephalopathy diagnosis. One study involving 99 patients with encephalopathy provided patients with a single 200mg dose per day for 30 days. Anxiety, pain, and depression levels were notably lower after treatment.
One study involving rodents sought to test the stimulating and cognitive enhancing properties of phenylpiracetam using passive avoidance and forced swim tests. The R enantiomer of phenylpiracetam was found to improve retention latency by 195% while both R and S enantiomers were found to reduce immobility time (suggesting an antidepressant effect) during a forced swim test, with the high dose R enantiomer being superior to S at doing so.